Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update
Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …
Clonal evolution in leukemia
AA Ferrando, C Lopez-Otin - Nature medicine, 2017 - nature.com
Human leukemias are liquid malignancies characterized by diffuse infiltration of the bone
marrow by transformed hematopoietic progenitors. The accessibility of tumor cells obtained …
marrow by transformed hematopoietic progenitors. The accessibility of tumor cells obtained …
Electrochemical biosensor for DNA methylation detection through hybridization chain-amplified reaction coupled with a tetrahedral DNA nanostructure
X Chen, J Huang, S Zhang, F Mo, S Su… - … applied materials & …, 2019 - ACS Publications
DNA methylation is a key factor in the pathogenesis of gene expression diseases or
malignancies. Thus, it has become a significant biomarker for the diagnosis and prognosis …
malignancies. Thus, it has become a significant biomarker for the diagnosis and prognosis …
An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
Targeted therapies against the BCR-ABL1 kinase have revolutionized treatment of chronic
phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) …
phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) …
Chronic myeloid leukemia: beyond BCR-ABL1
Purpose of review In this review, we emphasize up-to-date practical cytogenetic and
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …
Pharmacogenomics of impaired tyrosine kinase inhibitor response: lessons learned from chronic myelogenous leukemia
M Kaehler, I Cascorbi - Frontiers in Pharmacology, 2021 - frontiersin.org
The use of small molecules became one key cornerstone of targeted anti-cancer therapy.
Among them, tyrosine kinase inhibitors (TKIs) are especially important, as they were the first …
Among them, tyrosine kinase inhibitors (TKIs) are especially important, as they were the first …
DNA methylation: a saga of genome maintenance in hematological perspective
In recent years, an explosion of interest for genome methylation in hematopoietic stem cells
(HSCs) differentiation and transplantation has been observed. The differentiation and timely …
(HSCs) differentiation and transplantation has been observed. The differentiation and timely …
[HTML][HTML] An overview of myeloid blast-phase chronic myeloid leukemia
GE Pamuk, LA Ehrlich - Cancers, 2024 - mdpi.com
Myeloid blast-phase chronic myeloid leukemia (MBP-CML) is a rare disease with a dismal
prognosis. It is twice as common as lymphoid blast-phase CML, and its prognosis is poorer …
prognosis. It is twice as common as lymphoid blast-phase CML, and its prognosis is poorer …
[HTML][HTML] Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options
The onset of global epigenetic changes in chromatin that drive tumor proliferation and
heterogeneity is a hallmark of many forms of cancer. Identifying the epigenetic mechanisms …
heterogeneity is a hallmark of many forms of cancer. Identifying the epigenetic mechanisms …
Philadelphia chromosome-positive leukemia in the lymphoid lineage—similarities and differences with the myeloid lineage and specific vulnerabilities
L Komorowski, K Fidyt, E Patkowska… - International Journal of …, 2020 - mdpi.com
Philadelphia chromosome (Ph) results from a translocation between the breakpoint cluster
region (BCR) gene on chromosome 9 and ABL proto-oncogene 1 (ABL1) gene on …
region (BCR) gene on chromosome 9 and ABL proto-oncogene 1 (ABL1) gene on …